nach oben

Reactions Weekly

Erschienen in:

01.04.2018 | Case report

Melphalan

Neuralgic amyotrophy: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

» Editorial comment: Details of this case report have previously been published [see Reactions 1695 p155; 803309995]. In this article, the dose of melphalan was mentioned as 200 mg/m2 for both the patients, the ADR neuralgic amyotrophy was also known as brachial plexopathy as stated by author and additional laboratory tests relevant to ADR were mentioned. The drugs dexamethasone and rituximab were ruled out as suspects for second patient because temporal causality was given in the introduction part of article. …

Nguyen VP, et al. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation 53: 371-373, No. 3, Mar 2018. Available from: URL: http://doi.org/10.1038/s41409-017-0048-6 - USACrossRefPubMed

Titel: Melphalan
Neuralgic amyotrophy: 2 case reports
Publikationsdatum: 01.04.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-45167-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Melphalan

Neuralgic amyotrophy: 2 case reports

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Adalimumab

Aspirin/clopidogrel

Ceritinib/crizotinib

Abatacept/methotrexate

Sorafenib

Bupivacaine/fentanyl